• Organizations: Aurion Biotech
Alcon purchases majority stake in Aurion Biotech
Business

Alcon purchases majority stake in Aurion Biotech

Company replaces CEO and founder Greg Kunst, gaining access to groundbreaking CED cell therapy with plans for phase 3 clinical trials expected later this year.
Aurion Biotech releases topline phase 1/2 data on allogeneic cell therapy for CED
Pipeline

Aurion Biotech releases topline phase 1/2 data on allogeneic cell therapy for CED

Findings support potential for high-dose AURN001 as a one-time intracameral injection that regenerates healthy cells from a single donor cornea.
KOLs eye the future of genetic engineering and cell transplantation
Events

KOLs eye the future of genetic engineering and cell transplantation

Industry leaders from four leading ophthalmic companies debut the latest clinical developments in cell-based therapeutics.
FDA grants Breakthrough Therapy Designation, RMAT to Aurion's CED cell therapy
Pipeline

FDA grants Breakthrough Therapy Designation, RMAT to Aurion's CED cell therapy

AURN001 is now the first allogeneic cell therapy to be granted two designations for corneal edema secondary to CED.
Aurion doses first Canadian patient in allogeneic cell therapy trial for CED
Pipeline

Aurion doses first Canadian patient in allogeneic cell therapy trial for CED

Corneal endothelial dysfunction candidate is being studied across clinical sites in North America.